Evidence map›Paper›PMID 37189891›Full record

ArticleChildren (Basel, Switzerland)2023

Mucopolysaccharidosis Type I in Mexico: Case-Based Review.

Consuelo Cantú-Reyna, Diana Laura Vazquez-Cantu, Héctor Cruz-Camino, Yuriria Arlette Narváez-Díaz, Óscar Flores-Caloca, Óscar González-Llano, Carolina Araiza-Lozano, René Gómez-Gutiérrez

Open access · goldAbstract readCase Reports
In one paragraph

Article in Children (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Consuelo Cantú-ReynaEscuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey 64710, Mexico.
Diana Laura Vazquez-CantuMedical Department, Genomi-k, Monterrey 64060, Mexico.
Héctor Cruz-CaminoEscuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey 64710, Mexico.ORCID 0000-0002-2815-6619
Yuriria Arlette Narváez-DíazCentro Médico, ISSSTELEON, Monterrey 64000, Mexico.
Óscar Flores-CalocaCentro Médico, ISSSTELEON, Monterrey 64000, Mexico.
Óscar González-LlanoEscuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey 64710, Mexico.
Carolina Araiza-LozanoMedical Department, Genomi-k, Monterrey 64060, Mexico.
René Gómez-GutiérrezEscuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey 64710, Mexico.
National Institute of Genomic Medicine · MXInstitute for Social Security and Services for State Workers · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMucopolysaccharidosis type I (MPS I) is a lysosomal storage disease present in 1:100,000 newborns. Variants in the IDUA (alpha-L-iduronidase) gene decrease the enzyme activity for glycosaminoglycans metabolism. MPS I patients exhibit clinical manifestations that fall on the Hurler, Hurler-Scheie, and Scheie syndrome spectrum. CASE PRESENTATION: We present a male Mexican patient with respiratory exacerbations requiring recurrent hospitalizations. He showed macrocephaly, coarse facies, hepatomegaly, umbilical hernia, and dorsal kyphosis. The sequencing of the IDUA gene revealed the following genotype: c.46_57del12/c.1205G>A. He received combined therapy with hematopoietic stem cell transplantation and enzyme replacement. Mexican case reports were analyzed to estimate the prevalence of the associated genetic variants.

conclusionDespite the challenges of managing this rare disease in Mexico, our patient benefited from the combined therapy. The discrete clinical manifestations and prompt evaluation by a geneticist were crucial in establishing a diagnosis, enabling an early intervention by a multidisciplinary team. The combination of ERT before and after HSCT provided health benefits to our patient.

Indexed as

iduronidaseMexicoMucopolysaccharidosis I

Identifiers

PMID37189891
PMCPMC10136708
OpenAlexW4361274296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.